Mylan CEO makes $10M in 9 months

Not bad for nine months' work. Mylan CEO and Vice Chairman Robert Coury (photo) brought down $10.3 million during fiscal 2007, which ran only nine months because the drugmaker changed its fiscal year.

Coury earned salary of about $1.12 million, stock awards of $1.15 million, and about $2.1 million in incentive compensation, the Pittsburgh Business Times reports. During the previous fiscal year, Coury was paid about $8.6 million. How does this compare to other drugmakers' executive pay? Well, it beats Pfizer's Jeff Kindler ($9.5 million) but doesn't outstrip Bristol-Myers Squibb's Jim Cornelius ($11.3 million) or even Cephalon's Frank Baldino ($13.5 million).

- read the Business Times story

ALSO: A federal appeals court affirmed a ruling that prevents Mylan from selling a copycat form of Johnson & Johnson's Topamax before the epilepsy med's patent expires later this year. Report

Related Articles:
Mylan CEO intent on new global biz. Report
Glaxo to let Mylan make generic Paxil. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.